| Literature DB >> 32663521 |
Avi Dobrusin1, Fadi Hawa2, Mark Gladshteyn3, Paul Corsello3, Kevin Harlen4, Charlie X Walsh3, Latha Alaparthi5, Michael Weinstein6, Nadeem Baig7, Andrew Sousa8, Naresh T Gunaratnam9.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32663521 PMCID: PMC7352104 DOI: 10.1016/j.cgh.2020.07.014
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN: 1542-3565 Impact factor: 11.382
Patient Baseline Characteristics, Reason for Visit, and Technology Platform Used
| Patient characteristics | n = 1492 |
|---|---|
| Age, | N (%) |
| 17–24 | 24 (1.6) |
| 25–34 | 69 (4.6) |
| 35–44 | 96 (6.4) |
| 45–54 | 170 (11.4) |
| 55–64 | 350 (23.5) |
| 65–74 | 496 (33.2) |
| 75–84 | 249 (16.7) |
| ≥85 | 38 (2.5) |
| Sex | |
| Female | 965 (64.7) |
| Visit reason | |
| Abdominal pain | 173 (11.6) |
| Constipation | 68 (4.6) |
| Diarrhea | 75 (5.0) |
| Diverticular disease | 40 (2.7) |
| GI bleed and/or anemia | 33 (2.2) |
| Heartburn/GERD | 173 (11.6) |
| Hemorrhoids/anal fissure/rectal pain | 47 (3.2) |
| Hepatic/biliary/pancreatic disorder | 66 (4.4) |
| Inflammatory bowel disease | 111 (7.4) |
| Irritable bowel syndrome | 42 (2.8) |
| Medication-related (including renewal and follow-up evaluation) | 59 (4.0) |
| Nausea/vomiting | 23 (1.5) |
| Procedure-related (including preparation and follow-up evaluation) | 248 (16.6) |
| Swallowing/esophageal disorder | 41 (2.7) |
| Other | 171 (11.5) |
| Unspecified follow-up evaluation | 122 (8.2) |
| Technology platform used | |
| Laptop/desktop | 836 (56.0) |
| Smartphone/tablet | 585 (39.2) |
| Telephone (audio-only) | 67 (4.5) |
| Unknown | 4 (0.3) |
GERD, gastroesophageal reflux disease; GI, gastrointestinal.
Figure 1(A) Patients’ approval rates to telehealth stratified by age groups. (B) Providers’ approval rates to telehealth. GI, gastrointestinal.
Supplementary Figure 1Patients’ approval rates stratified by visit reason. GERD, gastroesophageal reflux disease; GI, gastrointestinal.
Supplementary Figure 2Providers’ expectations of telehealth use in the future.